Welcome to our dedicated page for Ginkgo Bioworks Holdings news (Ticker: DNA), a resource for investors and traders seeking the latest updates and insights on Ginkgo Bioworks Holdings stock.
Ginkgo Bioworks Holdings Inc (NYSE: DNA) operates at the forefront of synthetic biology, combining cell programming expertise with biosecurity solutions for industries ranging from pharmaceuticals to agriculture. This news hub provides investors and industry professionals with essential updates on the company's strategic initiatives and technological advancements.
Access real-time announcements including earnings reports, R&D breakthroughs, and strategic partnerships that demonstrate Ginkgo's leadership in biological engineering. The platform serves as a comprehensive resource for tracking developments in their core Cell Engineering services and Biosecurity programs.
Discover updates on Ginkgo's AI-driven innovations, government contracts, and cross-industry collaborations that shape the future of synthetic biology. Content is curated to help stakeholders understand how biological engineering advancements translate to commercial opportunities.
Bookmark this page for streamlined access to verified financial disclosures, operational milestones, and analysis of emerging trends in cell programming technology. Regular updates ensure you stay informed about developments impacting DNA's market position and sector leadership.
Phytolon and Ginkgo Bioworks (NYSE: DNA) have achieved a significant milestone in their natural food colors collaboration, nearly tripling manufacturing efficiency. The partnership, initiated in 2022, focuses on developing yeast strains to produce two natural colors: "Beetroot Red" and "Prickly Pear Yellow."
This breakthrough comes amid increasing pressure to eliminate artificial food dyes in the U.S., with FDA Commissioner Marty Makary announcing plans to remove synthetic colors from the food supply by 2026. The FDA has already banned FD&C Red No. 3 due to cancer risks.
The improved production process offers significant advantages:
- Higher production efficiency (3x increase)
- Reduced production costs
- Lower carbon footprint
- Successful coloring in multiple food categories including baked goods, snacks, dairy, and confectioneries
As part of the milestone achievement, Ginkgo will receive additional equity in Phytolon, strengthening their partnership in sustainable food coloring solutions.
Ginkgo Bioworks (NYSE: DNA), a leader in cell programming and biosecurity, has scheduled its Q1 2025 earnings presentation for Tuesday, May 6, 2025, at 5:30 p.m. ET. The company will review its business performance for the quarter ended March 31, 2025.
The presentation will be accessible through Ginkgo's investor relations website at investors.ginkgobioworks.com, with a replay option available. Stakeholders can submit questions beforehand via:
- X (formerly Twitter) using @Ginkgo and #GinkgoResults
- Email at investors@ginkgobioworks.com
Ginkgo Bioworks (NYSE: DNA) has announced a strategic partnership with Aura Genetics to deploy its Reconfigurable Automation Cart (RAC) system at Aura's new high-throughput facility in Louisville, KY. The collaboration aims to enhance Aura's direct-to-consumer testing capabilities.
The RAC system will be installed at Aura's new 22,000-square-foot facility at the UPS Healthcare Labport. With Ginkgo's automation technology and support services, Aura Genetics expects to process tens of thousands of samples daily. The agreement includes comprehensive support through joint protocol development, biovalidation, and dedicated technical assistance.
Ginkgo Bioworks (NYSE: DNA) has secured a $29 million contract from ARPA-H for a two-year program called WHEAT (Wheat-based High efficiency Enzyme and API Technology). The project, in partnership with Tritica Biosciences, US Pharmacopeia, On Demand Pharmaceuticals, and Isolere Bio by Donaldson, aims to develop a revolutionary pharmaceutical manufacturing process.
The initiative focuses on creating distributed production of biologic and small molecule active pharmaceutical ingredients (APIs) using wheat germ cell-free expression systems. This innovative approach seeks to shift API production from global supply chains to a decentralized system using Cell-Free Protein Synthesis (CFPS), potentially reshoring and stabilizing supply chains for essential medicines.
The WHEAT program will demonstrate scalable processes for CFPS-based production of complex APIs, with applications ranging from small molecule compounds to biologics like growth factors and insulin. Ginkgo will contribute its cell programming platform, utilizing machine learning and computational tools to engineer enzymes and optimize cell-free expression systems.
Ginkgo Bioworks (NYSE: DNA) reported Q4 2024 results with total revenue of $44 million, up from $35 million year-over-year. Cell Engineering revenue grew 29% to $35 million, while Biosecurity revenue reached $9 million.
The company reported a Q4 GAAP net loss of $(108) million, improved from $(212) million in the prior year. Cash position stood at $562 million as of December 31, 2024, with Q4 cash flow of $(55) million, better than Q3's $(114) million.
For full-year 2024, total revenue decreased 10% to $227 million. The company achieved $190 million in annualized cost reductions and targets $250 million by Q3 2025. 2025 Guidance: Total revenue of $160-180 million, including Cell Engineering revenue of $110-130 million and Biosecurity revenue of at least $50 million.
Ginkgo Bioworks (NYSE: DNA) has integrated the Callisto™ Sample Prep System into their routine Illumina sequencing workflow. The system, developed by Volta Labs, addresses the automation challenges in DNA clean-up processes, particularly for high-throughput labs handling thousands of samples.
The Callisto system features an App Store concept that enables access to multiple sequencing technologies and chemistries on a single platform, helping maintain low operating costs. A notable addition is the Size Selection app, which allows short-read labs using Illumina, Element Biosciences, and Ultima Genomics platforms to purify and select optimal fragment sizes for sequencing.
The system's advanced electrowetting, magnetic, and acoustic capabilities, along with its proprietary VoltaNode™ technology, enable precise liquid separation, efficient DNA elution from beads, and flexible batch processing.
Ginkgo Bioworks (NYSE: DNA) has announced a partnership with the European Health and Digital Executive Agency (HaDEA) in a consortium project worth up to €24 million over 4 years. The project, named RANGER (RApid Next Generation Sequencing for Effective Medical Response), aims to develop a rapid point-of-care diagnostic solution for respiratory viruses.
The initiative will create a device capable of identifying virtually any respiratory pathogen through metagenomic next-generation sequencing (mNGS) with a 6-hour turnaround time. The program includes an option for the European Commission to procure 200 devices at preferred pricing.
The project will be executed in three phases, involving technology development with partners Jumpcode, TGen, Bugseq, and Planet Innovation, followed by clinical trials in EU hospitals, and finally EU certification. The consortium includes partnerships with KU Leuven, Karolinska University Hospital, and Tartu University Hospital for clinical trials.
Ginkgo Bioworks (NYSE: DNA) has scheduled its Q4 and full year 2024 financial results presentation for Tuesday, February 25, 2025, at 5:30 p.m. ET. The presentation will include a business performance review and Q&A session.
Investors can access the presentation and webcast through Ginkgo's investor relations website, with a replay option available afterward. Questions can be submitted in advance via X (using #GinkgoResults) or email to investors@ginkgobioworks.com.
Ginkgo Bioworks (NYSE: DNA) has announced its 2025 Ferment Series, transforming its annual conference into multiple focused events throughout the year at their Boston Seaport District venue. The series will showcase Ginkgo's cell engineering and biosecurity offerings, featuring presentations from company experts, partners, and industry leaders.
The events will highlight new products and services, including Ginkgo Datapoints' AI-driven data generation services, Ginkgo Automation's Reconfigurable Automation Cart systems, and Ginkgo Biosecurity's product suite featuring Canopy and Horizon platforms.
The series includes four main events: Summer's Datapoints x AI focus on biotech R&D, September's Biopharma Solutions showcase, October's Biosecurity discussions, and November's Automation demonstrations. Additionally, Ginkgo will participate in World AgriTech in San Francisco (March) and ABIM (October), including a tour of their West Sacramento R&D facility. A larger, platform-wide Ferment will return in 2026.
Ginkgo Bioworks (NYSE: DNA) announced that its Ginkgo Automation division will design and deploy a flexible laboratory automation system for the Great Lakes Bioenergy Research Center (GLBRC) at the University of Wisconsin–Madison. The system aims to support biofuels and bioproducts research from plant biomass.
The new anaerobic-capable automation system will enable GLBRC scientists to run multiple experiments simultaneously across both aerotolerant and anaerobic conditions, increasing efficiency and 'walkaway' time. The system includes access to Catalyst Flow, a remote error resolution service expected to resolve 80-90% of system errors without user intervention.
Built on expertise from Ginkgo Bioworks and Zymergen, the customizable system focuses on automating workflows for anaerobic organisms, a key requirement for GLBRC's research programs. The technology aims to help GLBRC advance its mission of enabling cost-effective, sustainable biofuel production at scale.
FAQ
What is the current stock price of Ginkgo Bioworks Holdings (DNA)?
What is the market cap of Ginkgo Bioworks Holdings (DNA)?
